- Home
- TYL vs EXEL Comparison
TYL vs EXEL Comparison
Compare TYL & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TYL | EXEL |
|---|---|---|
| Founded | 1966 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 11.4B |
| IPO Year | 1996 | 2000 |
Fundamental Metrics
Financial Performance| Metric | TYL | EXEL |
|---|---|---|
| Price | $295.74 | $53.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 21 |
| Target Price | ★ $476.50 | $46.50 |
| AVG Volume (30 Days) | 739.9K | ★ 2.2M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 19.01 | ★ 57.95 |
| EPS | ★ 1.88 | 0.79 |
| Revenue | ★ $493,101,000.00 | $452,477,000.00 |
| Revenue This Year | $9.55 | $13.61 |
| Revenue Next Year | $9.75 | $13.13 |
| P/E Ratio | $157.16 | ★ $67.70 |
| Revenue Growth | ★ 18.35 | N/A |
| 52 Week Low | $283.72 | $33.76 |
| 52 Week High | $621.34 | $53.93 |
Technical Indicators
Market Signals| Indicator | TYL | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 41.07 | 61.94 |
| Support Level | $289.04 | $40.17 |
| Resistance Level | $361.86 | N/A |
| Average True Range (ATR) | 11.06 | 1.54 |
| MACD | -0.67 | 0.08 |
| Stochastic Oscillator | 23.62 | 86.10 |
Price Performance
Historical ComparisonAbout TYL Tyler Technologies Inc.
Tyler Technologies provides a full suite of software solutions and services that address the needs of cities, counties, schools, courts and other local government entities. The company's three core products are Munis, which is the core ERP system, Odyssey, which is the court management system, or CMS, and payments. The company also provides a variety of add-on modules and offers outsourced property tax assessment services.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.